172 related articles for article (PubMed ID: 18637482)
1. Adaptation to estradiol deprivation causes up-regulation of growth factor pathways and hypersensitivity to estradiol in breast cancer cells.
Santen RJ; Song RX; Masamura S; Yue W; Fan P; Sogon T; Hayashi S; Nakachi K; Eguchi H
Adv Exp Med Biol; 2008; 630():19-34. PubMed ID: 18637482
[TBL] [Abstract][Full Text] [Related]
2. Long-term estradiol deprivation in breast cancer cells up-regulates growth factor signaling and enhances estrogen sensitivity.
Santen RJ; Song RX; Zhang Z; Kumar R; Jeng MH; Masamura A; Lawrence J; Berstein L; Yue W
Endocr Relat Cancer; 2005 Jul; 12 Suppl 1():S61-73. PubMed ID: 16113100
[TBL] [Abstract][Full Text] [Related]
3. Adaptive hypersensitivity to estrogen: mechanism for superiority of aromatase inhibitors over selective estrogen receptor modulators for breast cancer treatment and prevention.
Santen RJ; Song RX; Zhang Z; Kumar R; Jeng MH; Masamura S; Yue W; Berstein L
Endocr Relat Cancer; 2003 Jun; 10(2):111-30. PubMed ID: 12790774
[TBL] [Abstract][Full Text] [Related]
4. Adaptive hypersensitivity to estrogen: mechanisms and clinical relevance to aromatase inhibitor therapy in breast cancer treatment.
Santen RJ; Song RX; Zhang Z; Kumar R; Jeng MH; Masamura S; Lawrence J; MacMahon LP; Yue W; Berstein L
J Steroid Biochem Mol Biol; 2005 May; 95(1-5):155-65. PubMed ID: 16024245
[TBL] [Abstract][Full Text] [Related]
5. Adaptive hypersensitivity to estrogen: mechanism for sequential responses to hormonal therapy in breast cancer.
Santen RJ; Song RX; Zhang Z; Yue W; Kumar R
Clin Cancer Res; 2004 Jan; 10(1 Pt 2):337S-45S. PubMed ID: 14734489
[TBL] [Abstract][Full Text] [Related]
6. Adaptive mechanisms induced by long-term estrogen deprivation in breast cancer cells.
Song RX; Santen RJ; Kumar R; Adam L; Jeng MH; Masamura S; Yue W
Mol Cell Endocrinol; 2002 Jul; 193(1-2):29-42. PubMed ID: 12160999
[TBL] [Abstract][Full Text] [Related]
7. Adaptive hypersensitivity to estradiol: potential mechanism for secondary hormonal responses in breast cancer patients.
Santen R; Jeng MH; Wang JP; Song R; Masamura S; McPherson R; Santner S; Yue W; Shim WS
J Steroid Biochem Mol Biol; 2001 Dec; 79(1-5):115-25. PubMed ID: 11850215
[TBL] [Abstract][Full Text] [Related]
8. Estrogen utilization of IGF-1-R and EGF-R to signal in breast cancer cells.
Song RX; Chen Y; Zhang Z; Bao Y; Yue W; Wang JP; Fan P; Santen RJ
J Steroid Biochem Mol Biol; 2010 Feb; 118(4-5):219-30. PubMed ID: 19815064
[TBL] [Abstract][Full Text] [Related]
9. Linkage of rapid estrogen action to MAPK activation by ERalpha-Shc association and Shc pathway activation.
Song RX; McPherson RA; Adam L; Bao Y; Shupnik M; Kumar R; Santen RJ
Mol Endocrinol; 2002 Jan; 16(1):116-27. PubMed ID: 11773443
[TBL] [Abstract][Full Text] [Related]
10. The role of Shc and insulin-like growth factor 1 receptor in mediating the translocation of estrogen receptor alpha to the plasma membrane.
Song RX; Barnes CJ; Zhang Z; Bao Y; Kumar R; Santen RJ
Proc Natl Acad Sci U S A; 2004 Feb; 101(7):2076-81. PubMed ID: 14764897
[TBL] [Abstract][Full Text] [Related]
11. Elevated ERK1/ERK2/estrogen receptor cross-talk enhances estrogen-mediated signaling during long-term estrogen deprivation.
Martin LA; Farmer I; Johnston SR; Ali S; Dowsett M
Endocr Relat Cancer; 2005 Jul; 12 Suppl 1():S75-84. PubMed ID: 16113101
[TBL] [Abstract][Full Text] [Related]
12. New approaches to the understanding of tamoxifen action and resistance.
Berstein LM; Zheng H; Yue W; Wang JP; Lykkesfeldt AE; Naftolin F; Harada H; Shanabrough M; Santen RJ
Endocr Relat Cancer; 2003 Jun; 10(2):267-77. PubMed ID: 12790788
[TBL] [Abstract][Full Text] [Related]
13. Enhanced estrogen receptor (ER) alpha, ERBB2, and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long term estrogen deprivation.
Martin LA; Farmer I; Johnston SR; Ali S; Marshall C; Dowsett M
J Biol Chem; 2003 Aug; 278(33):30458-68. PubMed ID: 12775708
[TBL] [Abstract][Full Text] [Related]
14. Molecular changes associated with the acquisition of oestrogen hypersensitivity in MCF-7 breast cancer cells on long-term oestrogen deprivation.
Chan CM; Martin LA; Johnston SR; Ali S; Dowsett M
J Steroid Biochem Mol Biol; 2002 Aug; 81(4-5):333-41. PubMed ID: 12361723
[TBL] [Abstract][Full Text] [Related]
15. Aromatase inhibitors: rationale for use following antiestrogen therapy.
Yue W; Santen RJ
Semin Oncol; 1996 Aug; 23(4 Suppl 9):21-7. PubMed ID: 8824461
[TBL] [Abstract][Full Text] [Related]
16. Adaptive hypersensitivity following long-term estrogen deprivation: involvement of multiple signal pathways.
Yue W; Wang JP; Conaway MR; Li Y; Santen RJ
J Steroid Biochem Mol Biol; 2003 Sep; 86(3-5):265-74. PubMed ID: 14623520
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms of acquired resistance to endocrine therapy in hormone-dependent breast cancer cells.
Yue W; Fan P; Wang J; Li Y; Santen RJ
J Steroid Biochem Mol Biol; 2007; 106(1-5):102-10. PubMed ID: 17616457
[TBL] [Abstract][Full Text] [Related]
18. Model systems: mechanisms involved in the loss of sensitivity to letrozole.
Brodie A; Jelovac D; Sabnis G; Long B; Macedo L; Goloubeva O
J Steroid Biochem Mol Biol; 2005 May; 95(1-5):41-8. PubMed ID: 15967659
[TBL] [Abstract][Full Text] [Related]
19. Long-term treatment with tamoxifen facilitates translocation of estrogen receptor alpha out of the nucleus and enhances its interaction with EGFR in MCF-7 breast cancer cells.
Fan P; Wang J; Santen RJ; Yue W
Cancer Res; 2007 Feb; 67(3):1352-60. PubMed ID: 17283173
[TBL] [Abstract][Full Text] [Related]
20. Adaptation of estrogen-regulated genes in long-term estradiol deprived MCF-7 breast cancer cells.
Santen RJ; Lobenhofer EK; Afshari CA; Bao Y; Song RX
Breast Cancer Res Treat; 2005 Dec; 94(3):213-23. PubMed ID: 16258703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
